Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer by González Martin, A et al.
Gynecologic Oncology 152 (2019) 53–60
Contents lists available at ScienceDirect
Gynecologic Oncology
j ourna l homepage: www.e lsev ie r .com/ locate /ygynoExploratory outcome analyses according to stage and/or residual disease
in the ICON7 trial of carboplatin and paclitaxel with or without
bevacizumab for newly diagnosed ovarian cancerAntonio González Martín a,⁎,1, Amit M. Oza b, Andrew C. Embleton c, Jacobus Pﬁsterer d,
Jonathan A. Ledermann e, Eric Pujade-Lauraine f, Gunnar Kristensen g, Monique A. Bertrand h, Philip Beale i,
Andrés Cervantes j, Emma Kent c,2, Richard S. Kaplan c, Mahesh K.B. Parmar c, Nana Scotto k,
Timothy J. Perren l, On behalf of the ICON7 investigators
a MD Anderson Cancer Center Spain, Madrid, Spain
b Princess Margaret Cancer Centre, University Health Network Toronto, 610 University Avenue, Toronto, ON M5G 2M9, Canada
c Medical Research Council Clinical Trials Unit at University College London (UCL), 90 High Holborn, London WC1V 6LJ, UK
d Gynecologic Oncology Center, Herzog-Friedrich-Str. 21, 24103 Kiel, Germany
e UCL Cancer Institute, 90 Tottenham Court Road, London W1T 4TJ, UK
f Hôpital Hôtel-Dieu, Assistance Publique – Hôpitaux de Paris, 1, Parvis Notre-Dame – Place Jean-Paul II, 75181 Paris CEDEX 04, France
g Department of Gynecologic Oncology and Institute for Cancer Genetics and Informatics, Radiumhospital, Oslo University Hospital, PO Box 4950, Nydalen, N-0424 Oslo, Norway
h Western University and London Health Sciences Centre, 800 Commissioners Road East, PO Box 5010, Stn B, London, ON N6A 5W9, Canada
i University of Sydney and Royal Prince Alfred Hospital, Level 6, Gloucester House, RPAH, Missenden Road, Camperdown, NSW 2050, Australia
j CIBERONC, Biomedical Research Institute INCLIVA, University of Valencia and Hospital Clínico de Valencia, Servicio de Hematología y Oncología Médica, Av. Blasco Ibáñez 17, 46010, Valencia,
Spain
k F. Hoffmann-La Roche Ltd, Building 1, Grenzacherstrasse 124, CH-4070 Basel, Switzerland
l Leeds Institute for Cancer Medicine and Pathology, St James's University Hospital, Beckett Street, Leeds LS9 7TF, UK
H I G H L I G H T S
• Post hoc analyses of ICON7 explored bevacizumab by stage and extent of residual disease after upfront surgery for OC.
• The progression-free survival (PFS) beneﬁt from bevacizumab was seen consistently in all subgroups explored.
• The PFS hazard ratio was 0.77 (95% CI, 0.59–0.99) in 411 patients with stage IIIB–IV disease and no visible residuum.
• No OS difference was detected overall or in any subgroup except the previously reported ‘high-risk’ subgroup.
• Adding bevacizumab to front-line chemotherapy improves PFS irrespective of stage/residual disease.⁎ Corresponding author.
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Available online 16 November 2018Objective. In the randomized phase 3 ICON7 trial (ISRCTN91273375), adding bevacizumab to chemotherapy
for newlydiagnosed ovarian cancer signiﬁcantly improvedprogression-free survival (PFS; primary endpoint) but
not overall survival (OS; secondary endpoint) in the intent-to-treat (ITT) population. We explored treatment ef-
fect according to stage and extent of residual disease.
Methods. Patients with stage IIB–IV or high-risk (grade 3/clear-cell) stage I–IIA ovarian cancer were random-
ized to receive six cycles of carboplatin and paclitaxel either alone or with bevacizumab 7.5mg/kg every 3weeks
followed by single-agent bevacizumab for 12 further cycles (total duration 12 months). Post hoc exploratory
analyses of subgroups deﬁned by stage and extent of residual disease at diagnosis within the stage IIIB–IV pop-
ulation (European indication) was performed.
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54 A. González Martín et al. / Gynecologic Oncology 152 (2019) 53–60ratio was 0.77 (95% conﬁdence interval [CI], 0.59–0.99) in 411 patients with stage IIIB–IV ovarian cancer with no
visible residuum and 0.81 (95% CI, 0.69–0.95) in 749 patients with stage IIIB–IV disease and visible residuum. As
in the ITT population, no OS difference was detected in any subgroup except the previously described ‘high-risk’
subgroup. Safety results in analyzed subgroups were consistent with the overall population.
Conclusions.Adding bevacizumab to front-line chemotherapy improves PFS irrespective of stage/residual dis-
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The anti-angiogenic agent bevacizumab is an established treatment
option for newly diagnosed disease and recurrent ovarian cancer,
based on signiﬁcantly improved progression-free survival (PFS) in ﬁve
large randomized phase 3 trials [1–5]. However, the optimal timing
and patient selection for bevacizumab have been longstanding topics
of debate, and an overall survival (OS) beneﬁt remains elusive. Explor-
atory biomarker research in subsets of patients has yielded inconsistent
results [6–9] and ﬁndings have not been validated in prospective trials
or even in exploratory analyses of other relevant datasets. In the ab-
sence of molecular markers predicting treatment effect, clinical charac-
teristics remain some of the most important factors in treatment
decision-making.
In the open-label randomized phase 3 ICON7 trial, PFS was signiﬁ-
cantly improved in patients receiving bevacizumab combined with
front-line carboplatin and paclitaxel and then continued as a single
agent for up to a total of 12 months compared with patients receiving
the same chemotherapy alone. The hazard ratio (HR) for PFS was 0.81
(95% conﬁdence interval [CI], 0.70–0.94; P = 0.004) [2]. No OS differ-
encewas detected in the intent-to-treat (ITT) population [10]. However,
exploratory analyses suggested improved OS with bevacizumab-
containing therapy in a predeﬁned subgroup of patients considered to
be at high risk of disease progression (International Federation of Gyne-
cology and Obstetrics [FIGO] stage III with residuum N1 cm, any FIGO
stage IV, or no debulking surgery). This subgroup was prospectivelyr
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led) according to residual disdeﬁned to facilitate comparison with the preceding GOG-0218 trial
population, which recruited only patients with FIGO stage IV disease
or incompletely resected stage III disease [1]. In GOG-0218, which also
demonstrated signiﬁcantly improved PFS but not OS with the addition
of bevacizumab to chemotherapy in the ITT population, exploratory
analyses of the protocol-speciﬁed ﬁnal OS analysis suggested that OS
was improved with bevacizumab in the subgroup of patients with
stage IV disease [11]. This patternwasmaintained in a recently reported
OS analysis with longer follow-up [12].
FIGO stage at diagnosis and extent of residual disease after debulking
surgery are both established prognostic factors in ovarian cancer. FIGO
stage has long been recognized as one of the most powerful determi-
nants of OS prognosis [13–17]. The correlation between maximal
cytoreduction (to no residual disease) and improved outcome is also
well documented [13,18–28]. However, relatively little is known about
the interaction between these factors in relation to prognosis, and it is
unclear whether surgical intervention or patient- and disease-related
factors are the main drivers of variation in prognosis [29].
In a series of 408 patients with stage IIIC ovarian cancer,
cytoreduction to no visible residual disease had a greater impact on
OS than the extent of metastatic disease before surgery [20]. However,
other reports suggested that factors beyond cytoreductive effort are im-
portant in predicting survival [30,31]. In an analysis of the GOG-0182
trial, patients withminimal residual disease after primary cytoreductive
surgery had worse PFS and OS than patients with complete resection
[32]. Interestingly, among patients with complete resection, thoseStage III
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Table 1
Baseline characteristics according to residual disease after primary debulking surgery.
Stage, n
No visible
residual
disease
Visible residual
disease
No
surgery
Total
≤1
cm,
NOS
N0–≤1
cm
N1
cm
I/II 232 14 29 7 0 282
III (no further
classiﬁcation)
11 1 8 11 1 32
IIIA 39 2 9 3 1 54
IIIB 46 4 25 14 0 89
IIIC 322 18 259 262 9 870
IV 43 2 39 98 19 201
Total 693 41 369 395 30 1528
NOS, not otherwise speciﬁed.
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and OS than those with low disease burden. Clearly complete resection
is an important goal, but how should patients with advanced disease
and complete resection be optimally treated if initial disease burden re-
mains such a powerful prognostic factor, irrespective of complete
resection?
It is difﬁcult to consider chemotherapy alone as an adequate op-
tion in this setting. For example, in the meta-analysis reported by
du Bois et al. [33], two-thirds of patients with stage IIIC disease and
complete resection at primary debulking surgery had relapsed
within 5 years, and among those with relapse or death, PFS events
occurred within 1 year of surgery in two-thirds of patients. Better
treatment options are needed for these patients, despite the im-
proved prognosis associated with complete resection. The role ofFig. 2. Subgroup analyses of efﬁcacy by stage. (A) progression-free survival; (B) overall
survival. CI, conﬁdence interval; HR, hazard ratio.bevacizumab in this setting is an important yet unanswered ques-
tion. The GOG-0218 trial provides no insight into this speciﬁc patient
population, as patients with stage III disease were eligible only if re-
sidual disease remained after primary debulking surgery [1]. There-
fore we aimed to address this question using the only available
dataset: ICON7. The prespeciﬁed subgroup analyses of the ICON7
trial classiﬁed residual disease as N1 cm, in line with clinical practice
at the time the analyses were planned. However, in contemporary
clinical practice, this deﬁnition is no longer acceptable and surgeons
strive for complete resection to maximize life expectancy. Therefore,
in this report, for most analyses we classiﬁed patients simply as hav-
ing residual disease or no visible residual disease after surgical
debulking.
2. Patients and methods
2.1. Study design
The design of the international open-label randomized phase 3
ICON7 trial has been described in previous publications [2,10]. In sum-
mary, women with newly diagnosed ovarian cancer that was either
high-risk early-stage (FIGO stage I–IIA, grade 3, or clear-cell histology)
or advanced (FIGO stage IIB–IV)were randomized after primary surgery
(unless disease was inoperable) to receive six cycles of chemotherapy
(carboplatin area under the curve 5–6 and paclitaxel 175 mg/m2, both
administered on day 1 every 3 weeks) either alone or in combination
with bevacizumab 7.5 mg/kg every 3 weeks continued for up to
12 months in the absence of disease progression or unacceptable toxic-
ity. Patients had to have Eastern Cooperative Oncology Group perfor-
mance status 0–2 and adequate coagulation parameters and liver,
renal, and bonemarrow function. Patients with uncontrolled hyperten-
sion were excluded, as were patients for whom further surgery was
planned.
The stratiﬁcation factors were: combined FIGO stage and residual
disease (stage I–III and ≤1 cm residual disease vs stage I–III and N1 cm
residual disease vs inoperable stage III and stage IV disease), planned in-
terval between surgery and chemotherapy (b4 vs ≥4weeks), and Gyne-
cologic Cancer InterGroup group.
The primary endpoint was PFS; the trial was also powered to de-
tect a difference in OS (secondary endpoint). Post hoc exploratory
analyses of subgroups deﬁned by stage at diagnosis and extent of re-
sidual disease were performed to assess consistency of PFS and OS
across subgroups.
Investigators assigned FIGO staging according to the 1998 FIGO
classiﬁcation, and reported extent of residual disease as optimal
(≤1 cm) or suboptimal (N1 cm) according to the classiﬁcation
scheme at the time the trial was designed. Further details of the ex-
tent of residual disease were collected retrospectively to provide
better understanding of the population treated in the ICON7 trial,
particularly in light of the GOG-0218 trial evaluating front-line
bevacizumab in a slightly different population that was reported in
the same year [1] and in accordance with contemporary clinical
practice, in which the goal is no visible residual disease. In the pres-
ent report, patients were categorized as having either visible resid-
ual disease or no visible residual disease. Nevertheless, we also
describe outcomes breaking down the visible residual disease cate-
gory into residuum N0–≤1 cm versus N1 cm according to categories
that were used before the Fourth Ovarian Cancer Consensus Confer-
ence [34]. Patients with minimal macroscopic residual disease (re-
siduum N0–≤1 cm) appear to have outcomes between those of
patients with complete resection and those with suboptimal dis-
ease, and therefore this population may merit consideration on its
own [35].
Tumors were assessed by computed tomography (CT) after cycles
3 and 6, and then 9 and 12 months after randomization. After treat-
ment discontinuation, CT scans were performed every 6 months
Fig. 3. Summary of PFS and OS in patients with stage IIIB–IV disease. CI, conﬁdence interval; HR, hazard ratio; OS, overall survival; PFS, progression-free survival.
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Disease progression was assessed by investigators according to Re-
sponse Evaluation Criteria in Solid Tumors (2000); radiological or
clinical evidence of progression was required.
2.2. Statistical analysis
The data cutoffs for these analyses were November 30, 2010, for PFS,
representing the updated primary PFS analysis requested by regulatory
authorities [2], andMarch31, 2013, for OS, representing theprespeciﬁed
ﬁnal OS analysis [10]. The 2010 cutoff for PFSwas chosen to avoid poten-
tial bias in PFS estimates during the extended OS follow-up, when CT
scans were performed only as clinically indicated. PFS was deﬁned as
the interval between the date of randomization and the date of ﬁrst pro-
gression or death, whichever occurred ﬁrst. Patients who were alive
without disease progression were censored at the date of last clinical
follow-up visit (i.e. using the same approach as the primary trial analy-
ses). In sensitivity analyses, patients who were alive and progression
free were censored at the date of their last tumor assessment.
Although the subgroup analyses reported here were not
prespeciﬁed in the primary and secondary objectives of the trial, a sta-
tistical analysis plan was developed (after study completion) and
agreed before performing these exploratory analyses. The main aim
was to assess consistency of treatment effects.
UnstratiﬁedCox regression analyseswereused to estimateHRs for PFS
and OS, presented with corresponding 95% CIs. Medians were estimated
using the Kaplan-Meier approach. As nonproportional hazards wereFig. 4. Subgroup analyses of efﬁcacy: (A) PFS and (B) OS; (i) Stage IIIB–IV (n=1160); (ii) Stag
disease (n= 749). CI, conﬁdence interval; HR, hazard ratio; OS, overall survival; PFS, progressdetected in the overall population of ICON7 [2], restricted means were
also calculated with associated 95% CIs for each subgroup. There was no
adjustment for multiplicity. Consequently, no P-values are presented.
3. Results
3.1. Patient population
The distribution of patients according to stage and residual disease is
shown in Fig. 1 and Table 1. In 41 patients classiﬁed as ‘optimally’
debulked, no further details of residual diseasewere available. These pa-
tients were included in the subgroup with visible residual disease.
3.2. Efﬁcacy
The median duration of follow-up was 28 months for PFS and
49 months for OS. Fig. 2 shows analyses by FIGO stage. For PFS, the sub-
groups for all stages indicate more favorable outcome with
bevacizumab (HRb1 in all subgroups). The 95% CIs are difﬁcult to inter-
pret because of the imbalance in sample size between the subgroups
(e.g. 163 patients with stage II disease, 1045 patients with stage III dis-
ease). Nevertheless, in all subgroups deﬁned by stage, the direction of
treatment effect favored bevacizumab. In contrast, the pattern for OS
is less clear. When interpreting these ﬁndings, the extremely low
event rates in the stage I and II subgroups compared with the stage III
and IV subgroups should be noted: OS analyses are based on only 15
events (13%) in the stage I subgroup and 27 (17%) in the stage IIe IIIB–IV with no visible residual disease (n= 411); (iii) Stage IIIB–IV with visible residual
ion-free survival.
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Fig. 5. Subgroup analyses by stage and residual disease status in the stage III/IV subgroup. CI, conﬁdence interval; HR, hazard ratio; NR, not reached; OS, overall survival; PFS, progression-
free survival.
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spectively, had died. Interpretation of PFS is hampered by similarly
low event rates in the lower stage subgroups (16%, 29%, 67%, and 84%
in the stage I, II, III, and IV subgroups, respectively).
PFS and OSwere also analyzedwithin themore restricted stage IIIB–
IV subgroup (corresponding to the approved indication for
bevacizumab in Europe). All patients in this subgroup, irrespective of re-
sidual disease status, derived a PFS beneﬁt from the addition of
bevacizumab to chemotherapy (Figs. 3 and 4), consistent with the ITT
population. The 95% CI of the HR for the smaller subgroup with stage
IIIB–IV disease and no visible residual disease (n = 411) was wide but
did not cross 1. Of note, the Kaplan-Meier curves for PFSwithin this sub-
group remained clearly separated over time (Fig. 4ii), in contrast to the
shape of the curves for the visible residual disease subgroup (Fig. 4iii)
and also the ITT population [2]. The absolute difference in PFS between
the bevacizumab-containing and chemotherapy-alone armswas similar
in all three analyses of the stage IIIB–IV subgroup (all patients, those
with no visible residual disease, and thosewith visible residual disease):
approximately 3 months as estimated by the restricted mean and ap-
proximately 5 months as estimated by the median. In contrast, no OS
difference was observed in either the entire stage IIIB–IV subgroup or
the subgroups further classiﬁed according to the presence/absence of
residual disease (Figs. 3 and 4). The 95% CIs for the OS HR crossed 1 in
all cases, indicating no difference in OS. This observation is consistent
with results in the ITT population.
Within the smaller subgroup of 43 patients with stage IV disease
and no visible residuum after debulking surgery, the PFS HRwas 0.88
(95% CI, 0.45–1.72). Median PFSwas 19.0months with bevacizumab-
containing therapy versus 13.0 months with chemotherapy alone. In
the subgroup of 158 patients with stage IV disease with visible resid-
uum after debulking surgery, the PFS HR was 0.63 (95% CI,
0.45–0.89) and median PFS was 13.2 months with bevacizumab-
containing therapy versus 9.6 months with chemotherapy alone.
Similar patterns were seen for OS in patients with stage IV disease:
in those with no visible residuum, the HR was 0.80 (95% CI,
0.36–1.76; median OS 49.2 vs 41.6 months with bevacizumab-
containing therapy vs chemotherapy alone, respectively), while in
those with visible residuum, the HRwas 0.69 (95% CI, 0.47–1.02; me-
dian OS 36.8 vs 26.3 months, respectively).
Among the broader group of patients with stage III/IV disease, the
important prognostic effect of extent of residual disease was seen
clearly in the median PFS and OS values in the chemotherapy-alone
arm, although the pattern was less clear in bevacizumab-treated pa-
tients, at least for PFS (Fig. 5). The magnitude of treatment effect on
OS (but not PFS) increased with increasing size of residuum within
the stage III/IV subgroup. The most pronounced effect of bevacizumab
therapy on both PFS and OS was in patients with residuum N1 cm.Sensitivity analyses within all of these subgroups showed very sim-
ilar results (data not shown).
3.3. Safety
Analyses of safety within the various subgroups deﬁned above
showed no relevant differences (Supplementary Table S1).
4. Discussion
In these post hoc exploratory analyses, adding bevacizumab to
carboplatin and paclitaxel chemotherapy improved PFS in most of the
evaluated subgroups, consistent with the ITT population. The main pa-
tient populations appearing not to derive a PFS improvement from
adding bevacizumab to chemotherapy were those with stage I or II dis-
ease, although small sample sizes and low event rates in these sub-
groups limit interpretation. In the subgroup of patients with stage
IIIB–IV disease, representing the approved bevacizumab indication in
Europe, a PFS improvement was seen irrespective of the presence or
not of visible residual disease.
Efﬁcacy in the stage IIIB–IV subgroup was consistent with results in
the ITT population for both PFS and OS.Within the subgroup of patients
with stage IIIB–IV disease, the important prognostic effect of visible re-
sidual disease extent was clearly reﬂected in the median PFS and OS
values in both the control arm and the investigational arm. The magni-
tude of bevacizumab treatment effect on PFS (as indicated by the HR)
was similar in patients with versuswithout visible residual disease, sug-
gesting that the extent of visible residual disease does not appear to be
predictive for bevacizumab treatment effect. In clinical practice, this
ﬁnding suggests that despite the better prognosis associated with com-
plete resection compared with visible residual disease after maximal
debulking, in both subgroups, PFS outcomes can be improved further
by addingbevacizumab to chemotherapy. RegardingOS in the subgroup
of patients with stage IIIB–IV disease, neither a beneﬁcial nor a detri-
mental effect from bevacizumab was demonstrated either in those
with complete resection or in those with visible residual disease. In
the stage IV subgroup, there was a trend toward improved OS with
bevacizumab but the 95% CI crossed 1, even in the small subgroup
with visible residual disease. This contrasts with observations from
GOG-0218, but as noted below, these exploratory subgroup analyses
should be interpreted with caution. Only in the previously reported
prespeciﬁed subgroup of patients with stage III residuum N1 cm, stage
IV, or inoperable disease (‘high-risk’ subgroup) has the PFS beneﬁt
translated into an OS beneﬁt [10].
These analyses have limitations that should be considered. Firstly,
these exploratory subgroup analyses were not prespeciﬁed in the pri-
mary analyses [2] and no adjustment was made for multiplicity of
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Secondly, the analyses rely on retrospectively collected information on
visible residual disease at the time of primary debulking. Thirdly, be-
cause the ICON7 trial recruitment period preceded the introduction of
the 2014 FIGO staging system, the analyses use the preceding FIGO stag-
ing system. The new staging appears to provide even better prognostic
value, at least for stage I–III disease [36]. Finally, we recognize that there
is a risk of bias in assessing PFS in an unblinded clinical trial. Despite
such limitations, these analyses expand our understanding of front-
line bevacizumab-containing therapy by providing an indication of the
effect of bevacizumab on outcomes in patientswith completely resected
advanced-stage ovarian cancer. This ﬁnding is pertinent given the prac-
tice in some countries and healthcare systems of restricting front-line
bevacizumab use to patients meeting the ICON7 criteria for high-risk
disease. Our ﬁndings also add to the analysis by Horowitz et al. [32],
which suggested that initial disease burden remained a signiﬁcant prog-
nostic indicator despite maximal cytoreduction to no residual disease.
Although complete resection remains a key goal in ovarian cancer, it is
important to avoid complacency in patients diagnosed with advanced-
stage disease to ensure that outcomes are optimized for patients, irre-
spective of surgical achievements.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.ygyno.2018.08.036.
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